Skip to content

Multicenter retrospective analysis of treatment decisions and prognosis in advanced breast cancer patients with heterogeneous disease progression after first-line treatment

Multicenter retrospective analysis of treatment decisions and prognosis in advanced breast cancer patients with heterogeneous disease progression after first-line treatment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033633
Enrollment
Unknown
Registered
2020-06-07
Start date
2020-08-01
Completion date
Unknown
Last updated
2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

case series:Nil

Sponsors

Guangdong Hospital of traditional Chinese Medicine Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with advanced breast cancer confirmed by histopathology or imaging; 2. Diagnosis time: January 2015 to June 2019; 3. Patients aged 18-75 years; 4. Women; 5. ECoG physical condition score: 0-2 points for patients; 6. Patients with target lesions (recist1.1 standard) that can be evaluated by imaging.

Exclusion criteria

Exclusion criteria: 1. Patients who have previously received immunotherapy for advanced breast cancer; 2. Patients with unmeasurable lesions (osteogenic metastasis, meningeal lesions, ascites, pleural effusion, pericardial effusion, pulmonary lymphangitis, abdominal masses and cystic lesions that cannot be diagnosed and followed up by imaging) in the initial diagnosis of advanced breast cancer; 3. Patients with middle nervous system metastasis; 4. Patients who received local treatment (surgery, radiotherapy) for primary or metastatic breast lesions; 5. Patients who did not receive regular follow-up and imaging evaluation; 6. Patients with missing clinicopathological data and follow-up data.

Design outcomes

Primary

MeasureTime frame
progression-free survival;

Secondary

MeasureTime frame
objective response rate;clinical benefit rate;

Countries

??

Contacts

Public ContactQianjun Chen

Guangdong Provincial Hospital of Chinese Medicine

cqj55@163.com+86 18688883505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026